Menu

With VISUDYNE®, you have a treatment option when it comes to patients experiencing:

  • An inadequate response
    to anti-VEGF therapy
  • Persistent retinal fluid
  • Injection fatigue

Persistent retinal fluid can be visualized using multiple imaging modalities1

Persistent retinal fluid can be visualized using multiple imaging modalities Persistent retinal fluid can be visualized using multiple imaging modalities

Key markers show presence of
persistent fluid

On fluorescein angiography (FA)1

  • Increased lesion size
  • New or persistent blood
  • Failure to resolve leakage
  • Enlargement of fibrosis

On optical coherence tomography (OCT)1

  • Intraretinal cysts
  • Subretinal fluid
  • Spongiform (variably reflective) fibrovascular posterior epithelial detachment (PED)
  • Serous PED

On fluorescein angiography (FA)1

  • Increased lesion size
  • New or persistent blood
  • Failure to resolve leakage
  • Enlargement of fibrosis

On optical coherence tomography (OCT)1

  • Intraretinal cysts
  • Subretinal fluid
  • Spongiform (variably reflective) fibrovascular posterior epithelial detachment (PED)
  • Serous PED

Have your patients been on anti-VEGF for an extended period of time?

CATT findings show that persistent fluid affects ~20% of wet AMD patients2,3

After 2 years of receiving anti-VEGF therapy as needed:

~1 in 5 patients
had persistent subretinal fluid2

1 in 5 patients had persistent subretinal fluid

~1 in 4 patients
had persistent intraretinal fluid3

1 in 4 patients had persistent intraretinal fluid

In one study, anti-VEGF injections were found to be a burden for some patients with wet AMD4

Patient-reported treatment challenges with ongoing anti-VEGF injections included:
Discomfort Anxiety Disruption of
normal activities		 Frequency of
treatment		 Injection
fatigue
SEE PATIENT PROFILES

AMD=wet age-related macular degeneration, anti-VEGF=anti-vascular endothelial growth factor, CATT=Comparison of Age-Related Macular Degeneration Treatment Trials evaluating ranibizumab vs bevacizumab for treatment of nAMD, CNV=choroidal neovascularization, FA=fluorescein angiography, OCT=optical coherence tomography.

Indication

VISUDYNE® (verteporfin for injection) therapy is a photoenhancer indicated for the treatment of patients with predominantly classic subfoveal choroidal neovascularization (CNV) due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis. There is insufficient evidence to indicate VISUDYNE for the treatment of predominantly occult subfoveal CNV.

Important Safety Information

  • VISUDYNE® (verteporfin for injection) is contraindicated for patients with porphyria or known hypersensitivity to any component of this preparation.
  • Standard precautions should be taken during infusion of VISUDYNE to avoid extravasation, including but not limited to:
    • A free-flowing intravenous (IV) line should be established before starting VISUDYNE infusion and the line should be carefully monitored.
    • Due to the possibly fragility of vein walls of some elderly patients, it is strongly recommended that the largest arm vein possible, preferably the antecubital, be used for injection.
    • Small veins in the back of the hand should be avoided.
  • Extravasation of VISUDYNE, especially if the affected area is exposed to light, can cause severe pain, inflammation, swelling or discoloration at the injection site. Necrosis at the injection site following extravasation has been reported. If extravasation does occur, the infusion should be stopped immediately. The extravasation area must be thoroughly protected from direct light until swelling and discoloration have faded in order to prevent the occurrence of local burn, which could be severe. Cold compresses should be applied to the injection site. Oral medication for pain relief may be administered.
  • Following injection with VISUDYNE, care should be taken to avoid exposure of skin or eyes to direct sunlight or bright indoor light for 5 days. If emergency surgery is necessary within 48 hours after treatment, as much of the internal tissue as possible should be protected from intense light.
  • Patients who experience severe decrease of vision of 4 lines or more within 1 week after treatment should not be retreated, at least until their vision completely recovers to pretreatment levels and potential benefits and risks of subsequent treatment are carefully considered by the treating physician.
  • Cases of anaphylactic reactions have been reported. Immediately discontinue VISUDYNE and initiate appropriate therapy if anaphylactic or other serious allergic reactions occur during or following therapy.
  • The most frequently reported adverse events (occurring in approximately 10%-30% of patients) were injection site reactions (including pain, edema, inflammation, extravasation, rashes, hemorrhage, and discoloration), and visual disturbances (including blurred vision, flashes of light, decreased visual acuity, and visual field defects, including scotoma).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Click here for full Prescribing Information for VISUDYNE®.

Indication and Important Safety Information

References: 1. Shah GK. Understanding and managing PDA in nAMD. Retina Today. March 2017 insert. 2. Core JQ, Pistilli M, Daniel E, et al. Predominantly persistent subretinal fluid in the comparison of age-related macular degeneration treatments trials. Ophthalmol Retina. 2021;5(10):962-974. doi: 10.1016/j.oret.2021.06.003. 3. Core JQ, Pistilli M, Hua P, et al. Predominantly persistent intraretinal fluid in the comparison of age-related macular degeneration treatments trials. Ophthalmol Retina. 2022;6(9):771-785. doi: 10.1016/j.oret.2022.03.024. 4. McClard CK, Wang R, Windham V, et al. Questionnaire to Assess Life Impact of Treatment by Intravitreal Injections (QUALITII): Development of a patient-reported measure to assess treatment burden of repeat intravitreal injections. BMJ Open Ophthalmol. 2021;6:e000669. doi:10.1136/bmjophth-2020-000669.